StockNews.AI
PGEN
StockNews.AI
159 days

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

1. Precigen will release 2024 financial results on March 19, 2025. 2. A conference call will discuss results at 4:30 PM ET that day. 3. The company specializes in innovative gene and cell therapies for urgent diseases. 4. Future results depend on the progress of clinical trials and studies. 5. Caution given on forward-looking statements regarding business expectations.

6m saved
Insight
Article

FAQ

Why Neutral?

Although announcing earnings dates is a routine update, it doesn't indicate immediate financial performance changes. Previous company announcements similar to this typically had a neutral to limited impact on stock prices.

How important is it?

The impact of the financial results on PGEN's stock is uncertain until actual data is released, leading to a moderate importance score. Earnings calls can generate investor interest, though they also come with cautionary risks.

Why Short Term?

Investors may react in the short term to the upcoming earnings call, but the earnings release is still a while away. Historically, stocks experience fluctuation just around earnings events, but broader market trends or performance may overshadow this impact.

Related Companies

CRSPZIOPBLCM
, /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations. Precigen: Advancing Medicine with Precision®Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube. Cautionary Statement Regarding Forward-Looking StatementsSome of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Investor Contact:Steven M. HarasymTel: +1 (301) 556-9850[email protected] Media Contacts:Donelle M. Gregory[email protected] SOURCE Precigen, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News